DRAGEN v3.7 released October 2020 | New features include:
The DRAGEN Platform can process NGS data for an entire human genome at 30× coverage in about 25 minutes on premise vs. > 15 hours with a traditional CPU-based system. It set two world speed records for genomic data analysis.2,3
When run on Illumina's BaseSpace Sequence Hub, analysis for a 30x genome is ~$5/sample and an exome at 100x coverage ~$3/sample.
In the 2020 PrecisionFDA Truth Challenge V2, DRAGEN won Difficult to Map Regions and All Benchmark Regions on Illumina Sequencing data.1
The DRAGEN Platform analyzes sequencing data from a variety of experiment types, including whole genomes, whole exomes, germline and somatic datasets, and RNA sequencing experiments.
Frequent releases continuously expand and improve the DRAGEN Platform while accommodating new applications and addressing evolving industry standards. DRAGEN updates are version controlled, enabling users to opt in or out of new updates as desired.
The DRAGEN team at Illumina is excited to announce winning Best Performance in the Difficult to Map Regions and All Benchmark Regions on Illumina Sequencing data. This win marks the start of major new capabilities that will be improved to include structural variants, copy number variations, and repeat expansions. Our success shows that we can now call variants with better accuracy than what was thought possible in difficult to map regions.Learn More
The DRAGEN Platform enables labs of all sizes and disciplines to do more with their genomic data. The DRAGEN Platform uses highly reconfigurable field-programmable gate array technology (FPGA) to provide hardware-accelerated implementations of genomic analysis algorithms, such as BCL conversion, mapping, alignment, sorting, duplicate marking, and haplotype variant calling. Fundamental features of the DRAGEN Platform address common challenges in genomic analysis, such as lengthy compute times and massive volumes of data.
Without compromising accuracy, the DRAGEN Platform delivers quickness, flexibility, and cost efficiency. The reprogrammable nature of the DRAGEN Platform enables Illumina to develop custom algorithms and allows for improvements to accommodate future applications.
|DRAGEN server||DRAGEN BaseSpace||NextSeq 1000/2000|
|Demultiplexing (BCL Convert)|
|Map & Align|
|RNA-Seq (gene fusion & quantification)|
|Exome enrichment (germline & somatic)|
|Whole genome (germline & somatic)||Germline only|
|TSO 500 Liquid|
|Pipeline||Description||Variant Types Detected||Metrics Provided|
|DRAGEN Demultiplexing||Rapid demultiplexing of NGS analysis||N/A||N/A|
|DRAGEN Map + Align||The DRAGEN Map + Align can be run as a standalone or as part of DRAGEN’s suite of pipelines||N/A||
|DRAGEN Germline||The DRAGEN Germline Pipeline provides end-to-end NGS analysis, including advanced error model calibration for increased accuracy, and repeat expansion detection and genotyping through Illumina Expansion Hunter.||
|DRAGEN Somatic||The DRAGEN Somatic Pipeline includes tumor-only and tumor–normal modes, designed for detecting somatic variants in tumor samples. Both modes make no ploidy assumptions, enabling detection of low-frequency alleles.||
|DRAGEN Enrichment||The DRAGEN Enrichment Pipeline combines DRAGEN’s germline and somatic callers into a pipeline designed specifically for analyzing enrichment samples. Includes a full suite of enrichment metrics and reporting.||
|DRAGEN RNA||The DRAGEN RNA Pipeline performs transcriptome analysis starting with splice junction discovery and alignment, followed by rapid alignment and splice junction mapping and quantification. For differential expression, Illumina recommends using the DeSeq 2 app on BaseSpace Sequence Hub.||
|DRAGEN Joint Genotyping||The DRAGEN Joint Genotyping/Population Pipeline calls variants jointly across multiple genomes and scales to large cohorts of samples at expedited speeds with uncompromising accuracy.||
|DRAGEN Methylation||The DRAGEN Methylation Pipeline performs alignment, methyl calling, and calculates alignment and methylation metrics.||N/A||
|DRAGEN Reference Builder||Accepts FASTA files, and builds the proprietary reference used by the DRAGEN apps.||N/A||N/A|
|DRAGEN TruSight Oncology 500 ctDNA Analysis Software||Secondary analysis support for Illumina’s TruSight Oncology 500 ctDNA. Only available on the local DRAGEN Server (version 3)||
Alexander Bisignano, cofounder and Chief Executive Officer of Phosphorus, discusses how the company uses the DRAGEN Bio-IT Platform to perform genomics data analysis onsite and at an accessible price point.Read Interview
Illumina is making it simpler for researchers to detect and identify SARS-CoV-2 and contribute their findings to the community with an integrated software toolkit, free of charge.Learn More
DRAGEN on BaseSpace Sequence Hub couples speed and accuracy of the DRAGEN Platform with the security, cost savings, and intuitive interface of BaseSpace Sequence Hub.
DRAGEN on-premise conducts secondary analysis in a fraction of the time compared with a traditional CPU-based system, while still maintaining high accuracy.
The on-board DRAGEN Bio-IT Platform offers an ultra-rapid, accurate solution for secondary analysis.
Collaborators Anthony Philippakis from The Broad Institute, and Susan Tousi of Illumina, discuss how integration of GATK with Illumina sequencers and implementation of the DRAGEN Platform may facilitate hardware acceleration and standardization of data analysis.View Video
Leveraging DRAGEN, GeneDx is now able to grow its operations while keeping costs low, turnaround times short, and accuracy high.Read Article
A Guinness world record was set for Fastest Genetic Diagnosis in 19.5 hours. The DRAGEN Platform was used to significantly increase the speed of mapping and aligning genomic data once sequenced.1Read Article
The DRAGEN Platform can be used for numerous applications in the biological sciences.
Rapidly analyze the sequenced genomes; accelerate reanalysis as computational tools improve over time.
Reduce time required for genomic analysis, when fast results can be a critical factor.
Accurate, rapid analysis of tumor-only and tumor/normal samples.
Analyze animals and plants of varying genomic complexities, using a provided reference.
Analyze targeted exome data with rapid turnaround and high accuracy to ensure reproducibility and high-quality results.
DRAGEN provides the flexibility to insert a variety of input files and produce a range of output documents. This flexibility enables users to customize their experience and use and produce their desired file format.
This diagram shows steps in the DRAGEN Germline Pipeline as an example. The actual steps vary for each pipeline.